AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02468323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Patients will receive slow intravenous injection of ondansetron 4 mg after cord clamping
Study NCT02468323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: Patients will receive slow intravenous injection of ondansetron 4 mg after cord clamping
Study NCT03998098 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory Rate
Description: Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers
Study NCT03998098 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Pressure
Description: Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers For participants only participating in the Blood Pressure Arm of the trial, they will not be required to enter the normobaric chamber but will have their blood pressure readings taken in the ambient environment including lying supine in order to generate hypotensive readings.
Study NCT00739934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voriconazole (Vfend)
Description: Study Days 1 to 7: IV voriconazole 7 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h~Notes:~1. If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~2. Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)
Study NCT02745990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Description: rhEPO is administered 500IU/kg, intravenously within 72h after birth, and every other day up to 32 weeks of corrected age.
Study NCT02745990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal salin is administered the same volume with rhEPO intravenously within 72h after birth, and every other day up to 32 weeks of corrected age..
Study NCT03577106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Description: Theta Burst Stimulation (TBS), a form of TMS, will be targeted to the Inferior Parietal Cortex based on neural navigation software. TBS will be delivered for about 5-6 minutes, five days a week for two weeks, for a total of ten sessions.
Study NCT01235520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral doses, once a day for 52 weeks
Study NCT01235520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: Oral dose level 1, once a day for 52 weeks
Study NCT01235520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: Oral dose level 2, once a day for 52 weeks
Study NCT01892436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT04527003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD) Extract
Description: Cannabis is a well-known plant that contains more than 500 identified phytochemicals of which over 100 are cannabinoids. The most widely studied is 9-tetrahydrocannabinol (9-THC), which is the major psychoactive component of Cannabis, but Cannabidiol (CBD) has been increasingly favored for its reduced side effect profile and potential health benefits. CBD was first isolated from Cannabis in the 1940s. CBD, unlike 9-THC, does not bind to CB1 and CB2 receptors, which accounts for its lack of typical psychotropic effects, but is still appears to work via alternative mechanisms via the endocannabinoid system.
Study NCT04527003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Norethindrone Acetate
Description: Norethindrone is a form of progesterone, a female hormone important for regulating ovulation and menstruation.
Study NCT04527003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norethindrone Acetate
Description: Norethindrone is a form of progesterone, a female hormone important for regulating ovulation and menstruation.
Study NCT04527003 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a substance or treatment which is designed to have no therapeutic value
Study NCT03523572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: The investigational product is a sterile lyophilized powder, which is made into solution for intravenous administration.
Study NCT03523572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an aqueous solution formulated at 10 mg/mL to be administered at a flat dose of 360 mg IV over 30 minutes. Protocol-defined thyroid testing is required while taking nivolumab.
Study NCT01851265 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Olaparib
Description: 400mg olaparib capsule formulation taken 30 minutes after allocated meal. 5-14 days between arms.
Study NCT01851265 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dietary Fasted
Description: Allocated breakfast prior to dosing with 400mg olaparib capsules
Study NCT01851265 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dietary standard
Description: Allocated breakfast prior to dosing with 400mg olaparib capsules
Study NCT01851265 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dietary High Fat
Description: Allocated breakfast prior to dosing with 400mg olaparib capsules
Study NCT04089241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast 3D Ultrasound
Description: an ultrasound examination which will include a 3D reconstruction and thereafter CEUS will be performed using SONOVIEW contrast agent
Study NCT02403817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: A collection of video games that rely on various aspects of visual behavior (i.e. sustained attention, vigilance, rapid discrimination, etc) for successful play.
Study NCT02403817 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: A collection of video games that rely on various aspects of visual behavior (i.e. sustained attention, vigilance, rapid discrimination, etc) for successful play.
Study NCT02403817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye Motor Training
Description: Game play will be controlled by the player's eye movements (via an eye tracking device)
Study NCT02403817 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hand Motor Training
Description: Game play will be controlled by the player's hand movements (via a joystick).
Study NCT00886886 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MDMA
Description: 125 mg, single dose
Study NCT00886886 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Reboxetine, 8 mg
Description: two doses 12h and 2h before MDMA
Study NCT00886886 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: capsules identical to MDMA or Reboxetine
Study NCT01461265 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cryoablation
Description: For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study and are at the discretion of the investigator.
Study NCT02468323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Patients will receive slow intravenous infection of palonosetron 75 mcg after cord clamping
Study NCT02468323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Palonosetron
Description: Patients will receive slow intravenous infection of palonosetron 75 mcg after cord clamping
Study NCT02790515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV prior to transplant on Day -1.
Study NCT02790515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given oral (PO) or IV beginning prior to transplant on Day -2. The dose will begin to taper at approximately day +60 after transplant in the absence of GVHD. Tacrolimus was used for the first 5 participants enrolled on study. Subsequent participants receive sirolimus.
Study NCT02790515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV prior to transplant on Day -3.
Study NCT02790515 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPC,A Infusion
Description: Hematopoietic Progenitor Cell, Apheresis (HPC,A) infusion of TCRɑβ+ depleted cells on day of transplant (Day 0) and HPC,A infusion of CD45RA+ depleted cells on Day +1 following transplant.
Study NCT02932176 — intervention group
Intervention type: DEVICE
Intervention: Non-invasive vascular testing
Description: Results of clinically indicated non-invasive vascular testing will be used to develop a machine learning algorithm
Study NCT02932176 — intervention group
Intervention type: DEVICE
Intervention: machine-learning algorithm
Study NCT02790515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
Study NCT02790515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given orally (PO) starting Day 0. The dose will be tapered off over two weeks starting on Day +42 in the absence of GVHD.
Study NCT01006239 — intervention group
Intervention type: OTHER
Intervention: No study intervention
Description: The is no study related intervention.
Study NCT04537195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADSMP-C
Description: A transdiagnostic, lay-led, group-based self-management program consisting of seven 2 ½ hour weekly sessions focusing on increasing patient self-efficacy in symptom management of anxiety and depression in cancer (ADSMP-C)
Study NCT03878095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsies
Study NCT03878095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT03878095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration and biopsy
Study NCT03878095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study NCT03195348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HBF Bed Rest
Description: 7 days of bed rest on hyper-buoyancy floatation (HBF)
Study NCT00442442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mosquito coils
Description: mosquito coil / night mosquito coil \& LLIN / night
Study NCT03878095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Given PO
Study NCT03878095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scans
Study NCT03878095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI scans
Study NCT03878095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT03560609 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ophthalmodynamometer
Description: The ODM (Baillart ophthlmodynamometer) is a disc attached to a piston that induces a controlled force on a fixed area. The device will be used to apply a pressure within the range of 10 mmHg - 50 mmHg 4 times to each eye. Each increase of pressure will last approximately 30 seconds. The device is FDA approved and will be used as routinely used in clinical practice
Study NCT03560609 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goldmann applanation tonometer
Description: The Goldmann applanation tonometer (Haag-Streit, Basel, Switzerland) measures the IOP after the eye is numbed with a drop of anesthetic (proparacaine), which is approved by the FDA. Proparacaine is part of routine patient care using a tonometer regardless of participation in this study. The instrument's tip lightly touches the surface of the cornea and the IOP is measured. The device is FDA approved is routinely used in clinical practice.
Study NCT03560609 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pentacam
Description: This device maps the cornea and provides pachymetry, topography and corneal aberration maps. The device is FDA approved and routinely used in clinical practice.
Study NCT03560609 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ORA
Description: ORA is an air puff tonometer that applies controlled force to flattens the cornea and provides the corneal hysteresis and corneal resistance factor. The device is FDA approved and routinely used in clinical practice.
Study NCT03560609 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optical Coherence Tomography (OCT)
Description: OCT is a non-contact,real-time, high resolution, and reproducible imaging modality that provides in-vivo optical cross-sectional scanning of the retina, the ONH and of the anterior segment structures including the cornea. Clinical staff will perform subject testing, not research coordinators. Information about these non-FDA approved OCTs and the multi-modal adaptive optics system can be found in appendices A, B, C, and D. With all devices, the participant sits in a slit lamp like frame. A low power laser light is projected toward the back of their eyes while the subject fixates on a target. None of the systems produce harmful radioactive radiation.
Study NCT00179465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiagabine
Description: Up to 36 mg daily
Study NCT00179465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00739362 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (TDCS)
Description: Active tDCS (anodal left DLPFC)
Study NCT04846933 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: WGS and RNA sequencing
Study NCT04846933 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: circulating tumor DNA (ctDNA)
Study NCT04846933 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FDG PET/CT imaging
Study NCT00739362 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (TDCS)
Description: Active tDCS (anodal left DLPFC)
Study NCT00442442 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LLIN
Description: Sleep under LLIN every night
Study NCT02703012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjustment of ventilator settings by EIT
Description: Diagnostic maneuvers (change in tidal volume, recruitment maneuvers) will be performed to detect overdistention, tidal recruitment and recruitability. Tidal volume will be reduced if overdistention is detected by EIT. Positive end-expiratory pressure will be increased if tidal recruitment or recruitability are detected.
Study NCT00919750 — intervention group
Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies
Study NCT00394251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin and Cytoxan (AC)
Description: Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide) make up the chemotherapy regimen known as AC. Adriamycin 60 mg/m\^2 intravenous, plus Cytoxan 600 mg/m\^2 intravenous on Day 1 of each of four 2-week cycles (weeks 1-8).
Study NCT00394251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: 260 mg/m\^2 IV on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
Study NCT00394251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: 175 mg/m\^2 intravenously (IV) on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
Study NCT00394251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg on day 1 of each of eight 2-week cycles (weeks 9-16), then 15 mg/kg on day 1 of each of ten three-week cycles (weeks 17-46).
Study NCT00394251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: 6 mg subcutaneous (SC) on day 2 for each of the first four 2-week cycles (weeks 1-8). Pegfilgrastim 6 mg SC was administered on day 2 of cycles 6-8 (weeks 11-16) during taxane treatment only if necessary.
Study NCT00588172 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Metformin
Description: 1000mg bid for 1 week
Study NCT00739362 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham/no-stimulation
Description: Sham tDCS
Study NCT04449198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 500 mg of oral trans-resveratrol twice daily (in the morning and evening) for 12-weeks
Study NCT04449198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo for 12 weeks
Study NCT03803774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant
Description: Given IV
Study NCT03803774 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRRT
Study NCT03803774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Biopsy
Description: Baseline and cycle 1 day 4 at week 1.
Study NCT03803774 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: Within 6 weeks pre-treatment, +/- 2 weeks 3 months post radiation treatment, and +/- 4 weeks at 6, 9,12,18 and 24 months post radiation treatment.
Study NCT03803774 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT Scan
Description: CT scan of the neck, chest, and upper abdomen with contrast at 6 weeks pre-treatment, +/- 2 weeks 3 months post radiation treatment, and +/- 4 weeks at 6, 9,12,18 and 24 months post radiation treatment.
Study NCT03803774 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI Scan
Description: MRI scan of the neck, chest, and upper abdomen with contrast at 6 weeks pre-treatment, +/- 2 weeks 3 months post radiation treatment, and +/- 4 weeks at 6, 9,12,18 and 24 months post radiation treatment.
Study NCT04285814 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Whole Fetal Cell (WFC) Testing
Description: Performing WFC testing on blood specimens.
Study NCT03223610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Administered orally, days 2-14, at varying doses of 200-800 mg (based upon assigned dose level); every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
Study NCT00588172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1000mg bid for 1 week
Study NCT02687529 — intervention group
Intervention type: DEVICE
Intervention: CST001
Study NCT03223610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Administered orally, days 1-14, at a dose of 560 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
Study NCT03223610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered orally, days 1-7, at a dose of 100 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
Study NCT03223610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Administered intravenously, days 1 and 2, at a dose of 1000 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
Study NCT03223610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid (lenalidomide)
Description: Administered orally, days 1-15, at a dose of 15 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
Study NCT03692052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: AG-348 tablet orally BID
Study NCT04362085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Anticoagulation
Description: The choice of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) will be at the clinician's discretion. LMWH options include: Tinzaparin, Enoxaparin or Dalteparin. UFH will be administered using a weight-based nomogram with titration according to center-specific institutional protocol.
Study NCT04608123 — intervention group
Intervention type: OTHER
Intervention: none (observational study)
Description: DBS